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Urinary excretion of glycosaminoglycans in normal and stone forming
subjects. There is evidence suggesting that glycosaminoglycans (GAG)
are potent inhibitors of growth and aggregation of calcium oxalate
crystals in vitro. This finding raises the possibility that the urinary GAG
could play an inhibitory role in the urolithiasis. To investigate this
hypothesis, a study on the urinary excretion of GAG in normal and
stone forming adults and chikren was undertaken. Different methods
were compared, and the best results were obtained when the GAG were
measured by densitometry after agarose gel electrophoresis. Although
the GAG concentration was increased in the morning urine compared to
the 24-hour urine samples, and in males compared to females, the
GAG/creatinine ratio was independent of period of urine collection and
of sex. So, it was advantageous to express the amounts of urinary GAG
as mg/g of creatinine. Children excreted more GAG than adults, with a
higher proportion of chondroitin sulfate, We have shown that the stone
forming subjects, both adults and children, excreted lower levels of
urinary GAG as compared to normal subjects, independently of the
metabolic disorder. The proportions between chondroitin sulfate and
heparan sulfate and the structures of these GAG were unaltered in the
stone formers. These results indicate that there is a definite difference in
terms of levels of GAG between normal and stone forming mines, and
suggest a correlation between the urinary GAG concentration and
urolithiasis.
A role for glycosaminoglycans (GAG) in the development and
regulation of lithiasis continues to challenge investigators in
urolithiasis research. Interest in GAG as contributors to the
regulation of stone formation had origins from in vitro studies
where commercial preparations of heparin and chondroitin
sulfates were found to be powerful inhibitors of calcium oxalate
crystallization [1—3]. The logical extension of these observa-
tions was that these polyanionic molecules in urine should play
an important role in the prevention of calculi. If urinary GAG
are important factors in the urolithiasis, one might expect
significant differences in the levels of GAG in the urine of stone
formers as compared to non-stone formers. Although Robert-
son et al [4] have suggested that a reduction in inhibitory
activity should be related to a decrease of GAG, attempts by
other investigators failed to find such a correlation [5—7]. On the
other hand, it was observed that the GAG isolated from the
urine of stone forming subjects form a precipitate with calcium
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ions, in contrast to the GAG from normal urine which gave no
precipitate [81. The stone former GAG have shown a higher
degree of sulfation and the investigators concluded that highly
sulfated glycosaminoglycans appear to be a significant factor in
calcium stone formation [8].
The present disparity of data may well reflect the techniques
used to assess the concentration and the structure of the urinary
GAG, as well as the inhibitory test applied.
In view of the increasing interest on this subject, it was
decided to examine the excretion patterns of the GAG in the
urine of normal and stone forming subjects. The concentration
of GAG was assessed by four different methods and the
structures of the isolated compounds were studied by chemical
and enzymatic analyses. The effects of time of day, sex, age and
metabolic disorders were also examined.
Methods
Urine
Complete 24-hour urine samples preserved with thymol crys-
tals (about 0.5 gIl) were collected from 23 healthy, active
subjects (11 males and 12 females) and from 51 stone-forming
subjects (25 males and 26 females) with ages ranging from 18 to
63 years, with normal renal function. For comparison, four-
hour urine samples were collected: at 8:00 a.m., each subject
emptied their bladder and discarded the sample. The bladder
was then emptied completely at 12:00 noon. A group of 26
healthy and 16 stone-forming children, ages ranging from 2 to 14
years, was also analyzed. The urine samples were stored at
—20°C. No dietary restrictions were maintained; for all pa-
tients, urinary tract abnormalities and/or urinary tract infection
were ruled out by X-ray and ultrasonographic examinations as
well as urinary cultures.
Other materials
Chondroitin 4-sulfate (from whale cartilage), chondroitin
6-sulfate (from shark cartilage) and dermatan sulfate (from pig
skin) were purchased from Miles Laboratories (Elkhart, Indi-
ana, USA). Heparan sulfate was prepared as already described
[9]. Chondroitinase AC and heparitinases I and II from Flavo-
bacterium heparinum were prepared as previously described
[10, 11]. 1,3 Diaminopropane was purchased from Aldrich
Chemical Co. (Milwaukee, Wisconsin, USA). Agarose and Bio
Gel P4 were obtained from Bio Rad Laboratories (Richmond,
California, USA). Toluidine Blue 0 was obtained from Fischer
Scientific Co. (Fairlawn, New Jersey, USA) and Alcian Blue
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Table 1. Urinary excretion of GAG in normal and stone forming subjects, assessed by different methods
Patient
Urinary glycosaminoglycans measured mg/liter
Dialyses and
electrophoresis
CTAB Gel filtration chromatography
complex
formation and Uronic
electrophoresis Electrophoresis acida
Alcian Blue
content of complex
Creatinine
g/liter
Normal subjects EA
EM
LA
20.16
22.02
22.50
12.26 9.40 29.50
10.13 10.72 20.50
11.16 12.74 43.15
25.87
22.99
44.26
1.46
1.58
2.00
Stone forming subjects AA
EO
IF
5.72
5.24
7.25
2.00 3.92 23.10
3.03 4.31 37.15
4.32 4.17 121.50
11.51
12.82
15.75
0.90
1.10
1.02
The numbers are mean values of three determinations.
a Expressed as mg of glucuronic acid per liter of urine
8GX from J.T. Baker Chemical Co. (Phillipsburg, New Jersey,
USA).
Isolation, quantification and characterization of GAG
Four different methods were used to assess the total GAG
concentration in urine.
Dialysis. Samples (5 to 10 ml) of urine were dialyzed against
distilled water for five hours at 4°C [12]. The dialyzed samples
were vacuum dried, resuspended in 50 d of water and aliquots
(5 j.d) were submitted to agarose gel electrophoresis [13]. The
GAG were measured by densitometry after Toluidine Blue
staining [13].
Precipitation with cetyltrimethylammonium bromide (CTAB).
The urinary GAG were precipitated from the urine by CTAB as
described by Meyer et al [14] and measured by densitometry
after agarose gel electrophoresis [13].
Ge/filtration chromatography. The urinary GAG were iso-
lated in a "macromolecular fraction" by gel filtration chroma-
tography on Bio Gel P4, as described by Hurst, Settine and
Lorincz [15]. Uronic acid was determined on a 0.5 ml aliquot
using glucuronic acid as a standard with the borate-carbazole
method [16]. Alternatively, I ml aliquots were vacuum dried,
resuspended in 5 l of distilled water and submitted to agarose
gel electrophoresis [13]. The GAG were measured by densitom-
etry after Toluidine Blue staining [13].
Precipitation with Alcian Blue. The GAG were determined by
the method of Whiteman [17, 18] as modified by Fellstrom et al
[7].
For preparative purposes, the GAG were isolated by precip-
itation with CTAB, as already described [14].
Studies regarding the recovery of added GAG were per-
formed by addition of chondroitin sulfate to urine samples (10
mg/liter of urine). These samples as well as control aliquots of
the same samples with no additions and a chondroitin sulfate
solution (10 mg/liter) were analyzed as described and the
recovery was measured.
The GAG were identified and quantitated by a combination of
agarose gel electrophoresis and enzyme degradation with spe-
cific mucopolysaccharidases [19]. The GAG quantifications
were performed by densitometry of the agarose gel slabs after
electrophoresis and staining by Toluidine Blue as previously
described [19]. The urinary GAG were fractionated by large
scale agarose gel electrophoresis in 0.05 M 1,3 diaminopropane
acetate buffer, pH 9.0, as already described [20]. The enzyme
degradations with chondroitinase AC were performed as de-
scribed by Michelacci and Dietrich [21] and with heparitinases
according to Silva, Dietrich and Nader [22]. The products
formed were chromatographed in 5:3 2-methylpropanoic acid—
1 M NH3 and quantitated as previously described [23]. The
molecular weight of the GAG were determined by polyacryl-
amide gel electrophoresis in gel slabs [9]. Amino sugars, uronic
acid and sulfate were determined by methods referred to
previously [23]. Creatinine was measured by the method of
Folin and Wu [24] as modified by Peters [25] except that all the
volumes were reduced to a half. Statistical differences were
determined using analysis of variance.
Criteria for the lithiasis diagnosis
Hypercalciuria occurs when 24-hour urinary calcium deter-
mination was higher than 4 mg/kg body wt. The subtypes of
hypercalciuria (renal hypercalciuria and absorptive hypercalci-
uria) were determined when the fasting urinary calcium/creati-
nine ratio was higher than 0.11. Absorptive hypercalciuria was
diagnosed when this ratio was lower than 0.11 and equal or
higher than 0.20, following oral calcium load test, as described
by Pak et al [26]. Hyperuricosuria was diagnosed for urinary
uric acid higher than 800 mg/24 hours for men and 750 mg/24
hours for women [27].
Results
Total urinary excretion of GAG assessed by different methods
The total urinary excretion of GAG was assessed by four
different methods and the results obtained for six urine samples
(three from normal and three from stone forming subjects) are
shown in Table 1. When the method was either dialysis or gel
filtration chromatography or precipitation with CTAB, the
urinary GAG were identified by agarose gel electrophoresis and
Toluidine Blue staining [19], which is a very specific and
sensitive method, avoiding the interference of non-GAG uri-
nary components.
The dialysis method gave results essentially identical to those
obtained when urine samples were concentrated and analyzed
for GAG by agarose gel electrophoresis, indicating that no loss
of GAG occurred during the dialysis. This result was corrobo-
rated by the finding that 90 to 95% of the chondroitin sulfate
added to urine samples was recovered after dialysis and agarose
gel electrophoresis.
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Table 2. General mean value and standard error of urinary excretion of GAG (mg/liter), creatinine (g/liter) and the GAG/creatinine ratio
(mg/g) in 24 hour and 4 hour periods of collection for normal and stone forming males and females
N
Glycosaminoglycans
mg/liter
Creatinine
gluier
Glycosaminoglycan/creatinine
mg/g
24 hr 4 hr224 hr 4 hr2 24 hr 4 hr8
Normal
Males 11 8.22 0.60 12.36 1.42 0.73 0.19 1.07 0.12 11.23 0.56 11.55 0.93
Females 12 7.97 0.43 9.88 1.37 0.63 0.09 0.73 0.10 12.67 1.26 13.53 1.21
Stone forming
Males 25 2.97 0.43 4.70 0.42 0.75 0.19 1.14 0.09 3.96 0.47 4.12 0.25
Females 26 2.32 0.24 4.76 1.21 0.63 0.03 1.07 0.47 3.68 0.47 4.45 0.53
a Between 8.00 a.m. and 12.00 a.m.
When the urinary GAG were estimated by the Alcian Blue
content of insoluble complexes, higher values were obtained,
indicating that urinary components other than GAG do form
complexes with Alcian Blue.
The values were even higher for the uronic acid measurement
after gel filtration chromatography and have shown no correla-
tion to the GAG identified by agarose gel electrophoresis in the
same samples. The recovery of chondroitin sulfate added to
urine samples was 50 to 70%, when the GAG were identified
and quantitated by agarose gel electrophoresis, and, again, have
shown no correlation to the uronic acid measurement by the
carbazole reaction (recovery 90 to 150%), suggesting the inter-
ference from other compounds present in the urine.
The recovery of added chondroitin sulfate was high for the
Alcian Blue method (94%). In contrast, only 45 to 60% of the
added chondroitin sulfate was recovered by precipitation with
CTAB.
Therefore, we decided to measure the urinary GAG by
agarose gel electrophoresis after dialysis, which is a reliable
method regarding absence of interference and adequacy of
recovery.
Influence of day time and of sex on the excretion of GAG and
creatinine
To investigate the time influence during the day upon the
excretion of GAG and creatinine, morning urine (4 hr) and
24-hour urine samples were analyzed (Table 2). A lower level
was observed for both GAG and creatinine in the 24-hour urine
samples (P < 0.05). Furthermore, in the morning urine, GAG
and creatinine concentrations were increased in males com-
pared to females (P < 0.05). Nevertheless, the differences were
not significant for the GAG/creatinine ratios (F> 0.10, NS).
On the other hand, stone forming subjects excrete signifi-
cantly lower levels of GAG when compared to normal subjects.
This difference is also observed in the GAG/creatinine ratios, as
the creatinine excretions in normal and stone forming subjects
are identical.
Urinary GAG in normal and stone forming adults and
children
Figure 1 shows the individual GAG/creatinine ratio for 23
normal and 51 stone-forming adults and for 26 normal and 16
stone-forming children. Children excreted more GAG than
adults (P < 0.001), but stone forming children presented signif-
icantly lower levels of urinary GAG than normal children (P <
0.001).
N SF N SF
Adults Children
FIg. 1. Urinaty GAG/creatinine ratios for normal and stone forming
subjects. Twenty-four-hour urine samples from 23 normal (N) and 51
stone forming (SF) adults and 26 normal and 16 stone forming children
were analyzed for GAG and creatinine as described in the text. Each
dot represents individual subject GAG/creatinine value and horizontal
bars represent mean value for each group.
The electrophoretic migration of the urinary GAG from
normal and stone forming adults and children are shown in
Figure 2 and the quantitative results are presented in Table 3.
The children excreted a higher proportion of chondroitin sulfate
when compared to adults (92% and 80%, respectively, P <
0.001) and these proportions are maintained in the stone form-
ers.
Influence of the metabolic abnormality on the urinary
excretion of GAG
Figure 3 shows the urinary GAG excretion in normal subjects
and in different subgroups of patients with nephrolithiasis. All
I
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Fig. 2. Agarose gel electrophoresis profile of the urinary GAG from
normal and stone forming subjects. Urine samples (10 ml) from normal
and stone forming adults and children were dialyzed against distilled
water, vacuum dried and resuspended in 50 d of water. Aliquots (5 tl)
were submitted to agarose gel electrophoresis in 0.05 M 1 ,3-diamino-
propane acetate buffer, pH 9.0 as previously described [141. The
compounds were quantitated by densitometry after Toluidine Blue
staining of the agarose gel slabs. The arrows indicate the electropho-
retic migration of standard GAG. CS, chondroitin sulfate; DS, derma-
tan sulfate; HS, heparan sulfate.
Table 3. Urinary excretion of total GAG, chondroitin sulfate (CS)
and heparan sulfate (HS) in normal and stone forming adults and
children (mean value SE)
Total GAG CS HS
N mg/g creat mg/g creat % mg/g creat %
Adults
Normal 23 11.98 0.73 9.58 0.64 80 2.40 0.09 20
Stone forming 51 3.82 0.23 3.02 0.19 79 0.80 0.04 21
Children
Normal 26 24.33 1.91 22.30 1.80 92 1.91 0.11 8
Stone forming 16 10.25 0.90 9.26 0.80 91 0.99 0.10 9
The data are expressed as mg of GAG/g of creatinine or as % of total
GAG.
the groups have shown a lower level of urinary GAG compared
to normal subjects (P < 0.001) but no significant differences
were detected among the different subgroups (P > 0.10, NS).
The proportions between chondroitin sulfate and heparan sul-
fate were also unaltered.
Characterization of the urinary chondroitin sulfate and
heparan sulfate
For preliminary studies on the structure of the urinary
chondroitin sulfate, 24-hour urine samples were pooled accord-
ing to the different subgroups of patients with nephrolithiasis
presented in Figure 3. A pool of normal urine samples was also
Fig. 3. Urinary excretion of GAG in normal and different subgroups of
stone forming subjects. Mean values of total GAG (•), chondroitin
sulfate () and heparan sulfate (LI) were determined for urine samples
of normal (N) and of different groups of patients with nephrolithiasis:
(AH) absorptive hypercalciuria; (RH) renal hypercalciuria; (HU) hy-
peruricosuric nephrolithiasis; (AH + HU) absorptive hypercalciuria +
hyperuricosuric nephrolithiasis; (RH + HU) renal hypercalciuria +
hyperuricosuric nephrolithiasis; (ND) non-determined metabolic abnor-
mality.
Table 4. Molecular weight of the chondroitin sulfates isolated from
pools of urine samples and degradation products formed from these
chondroitin sulfates by the action of chondroitinase AC
Molecular
Urine
weight kD
Modal Range
Disaccharides formed %
zDi4S Di6S Di0S
Normal 5 2—12 38 50 12
RH 5 2—12 35 56 9
AH 5 2—12 31 58 11
HU 5 2—12 35 57 8
RH+HU 5 2—12 37 57 6
AH + HU 5 2—12 33 56 11
ND 5 2—12 35 61 4
Abbreviations are: RH, renal hypercalciuria; AB, absorptive hyper-
calciuria; HU, hyperuricosuric nephrolithiasis; ND, non-determined
metabolic abnormatity; ADi4S, 2-acetamido-2-deoxy-3-0-(gluco-4-ene-
pyranosyluronic acid)-4-0-sulfo-D-galactose; zDi6S, 2-acetamido-2-de-
oxy-3-0-(gluco-4-enepyranosyluronic acid)-6-0-sulfo-D-galactose; ADiOS,
2-acetamido-2-deoxy-3-0-(gluco-4-enepyranosyluronic acid)-D-galactose.
prepared. The GAG were isolated from the pools by the CTAB
complex formation method [14] and were identified by agarose
gel electrophoresis. The chondroitin sulfate, which corresponds
to about 80% of the total urinary GAG, showed a modal
molecular weight of 5,000 daltons for normal urine and also for
all the metabolic abnormalities (Table 4). The relative amounts
of unsaturated 4-sulfated (ADi4S), 6-sulfated (Di6S) and non-
sulfated disaccharides (ADiOS) formed from the chondroitin
sulfates by degradation with chondroitinase AC are also shown
in Table 4. No significant differences were observed for the
chondroitin sulfates isolated from the different pools (P < 0.10,
NS). So, the urine samples of all the patients with nephrolithi-
asis were pooled, and the GAG were isolated as already
described and fractionated by large scale agarose gel electro-
phoresis. The chondroitin sulfate and heparan sulfate thus
obtained from normal subjects and from patients with nephro-
lithiasis were submitted to enzymic analyses, and the results
Normal Stone forming
2 4 2 4
HU AH+HU AH+HU ND
Pathology
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Table S. Enzymic analyses of the GAG isolated fr om the urine of normat and stone forming adults and children
Disaccharides formed from CS % Disaccharides formed from HS %
£Di45 ADi6S ADiOS ADiGIcNS6S ADiGIcNS ADiGIcNAc6S ADiG1cN
Adults
Normal
Stone forming
Children
Normal
Stone forming
37 50 13
37 53 10
47 39 14
48 37 15
18
14
ND
ND
55 9
52 12
ND ND
ND ND
18
22
ND
ND
Abbreviations are: CS, chondroitin sulfate; 115, heparan sulfate; ADiGIcNS6S, 2-sulfamino-2-deoxy-4-0-(glyco-4-enepyranosyluronic acid)-
6-0-sulfo-D-glucose; ADiGIcNS, 2-sulfamino-2-deoxy-4-0-(glyco-4-encpyranosyluronic acid)-D-glucose; ADiGIcNAc6S, 2-acetamido-2-deoxy-
4-0-(glyco-4-enepyranosyluronic acid)-6-0-sulfo-D-glucose; ADiGIcNAc, 2-acetamido-2-deoxy-4-0-(glyco-4-cnepyranosyluronic acid)-D-glucose;
ADi4S, ADi6S and ADiOS, as in legend of Table 4; ND, not determined.
Table 6. Chemical analyses of the GAG isolated from the urine of
normal and stone forming adults
Ilexosamine
lJronic
acid Sulfate
Molecular
weight kD
Modal Rangeai
Chondroitin sulfate
Adults
Normal 1.0 1.01 0.91 5 2—12
Stone forming 1.0 1.08 0.94 5 2—12
Children
Normal 1.0 1.19 0.92 5 2—12
Stone forming 1.0 1.17 0.85 5 2—12
Heparan sulfate
Adults
Normal 1.0 1.05 0.73 35 6—170
Stone forming 1.0 1.08 0.70 35 6—170
obtained for adults and children are presented in Table 5. The
chondroitin sulfates excreted by the children are composed of a
higher proportion of Di4S when compared to those excreted by
the adults. Nevertheless, the relative amounts of sulfated
versus non-sulfated disaccharides were very similar in the
chondroitin sulfates from normal and stone forming subjects.
This result was confirmed by the chemical analyses (Table 6).
The ratios of sulfate/hexosamine were identical in normal and
stone forming adults and children. The urinary heparan sulfates
from normal and stone forming adults have shown high molec-
ular weights an migrated as polydisperse bands in polyacryl-
amide gel electrophoresis (Table 6). No significant differences
in the sulfation levels of these compounds were observed by
either chemical or enzymic analyses (Tables S and 6).
Discussion
In vitro studies revealed that chondroitin sulfate and heparin
are inhibitors of the growth and aggregation of calcium oxalate
crystals [ii. If the urinary GAG play an inhibitory role in
urolithiasis, one might expect different levels of GAG in the
urine of stone formers compared to non-stone formers. Never-
theless, different results have been obtained by different inves-
tigators, which may reflect the methods which have been
employed [4—7, 28—30].
Many investigators use the Alcian Blue content of insoluble
complexes formed in urine as a measurement of GAG [7, 30].
Higher values are obtained by this method when compared to
the dialysis method here described, suggesting either a loss of
GAG during dialysis or the interference of other urinary com-
ponents that also form complexes with Alcian Blue. We have
shown a recovery of 90 to 95% for added chondroitin sulfate
after dialysis. Furthermore, it had been shown that the Alcian
Blue complex is reduced in only 1/3 after the degradation of the
urinary GAG with chondroitinase AC [31, which led the authors
to conclude that chondroitin sulfate corresponds to only 1/3 of
the total urinary GAG [3]. Nevertheless, it has been generally
accepted that chondroitin sulfate is the main GAG in normal
human urine [28, 29, 3 1—33], indicating that non-GAG urinary
components do interfere, forming insoluble complexes with
Alcian Blue. This finding should explain the disparity of data
obtained by different authors using this method [4, 301.
Interference of non-GAG urinary components was also de-
tected for the uronic acid measurement after gel filtration
chromatography. On the other hand, a low recovery was
obtained by precipitation of the urinary GAG with CTAB.
In the present study we have used the dialysis method, which
is a very reliable methodology to identify and quantitate GAG
and avoids either the interference of non-GAG urinary compo-
nents or a possible loss of GAG.
The GAG concentration was found to be increased by 20 to
30% in the morning urine compared to the 24-hour urine
samples. Furthermore, in the morning urine, the GAG concen-
tration was increased by 20% in males compared to females.
The excretion of creatinine, however, varied in the same way.
As a consequence, the excretion of GAG/creatinine was inde-
pendent of the period of urine collection and of sex. These
results make it advantageous to use the GAG/creatinine ratio.
In normal subjects we have shown that the urinary GAG are
in the range of 11 to 13 mg/g of creatinine for adults and 22 to 26
mg/g of creatinine for children, The main GAG are chondroitin
sulfate and heparan sulfate and our results have shown that
children excrete a higher proportion of chondroitin sulfate when
compared to adults (92% and 80% of total GAG, respectively).
In the studies of stone formation, it is necessary, however, to
keep in mind that urolithiasis is most probably a multifactorial
disease. Several predisposing factors, such as hypercalciuria,
hyperuricosuria and deficiency of inhibitors of crystal formation
and aggregation can play a role. As not all are likely to be
present in the same patients, it was decided to divide the
patients into subgroups, according to their pathophysiological
disturbance. All the subgroups have shown a lower level of
urinary GAG compared to normal subjects and the proportions
between chondroitin sulfate and heparan sulfate were unal-
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tered. Other investigators [30] claim higher GAG excretion
levels in patients with absorptive hypercalciuria, but their data
were based on Alcian Blue content of insoluble complexes
formed.
Even though enzymic analyses of the urinary chondroitin
sulfates with chondroitinase AC have shown a higher propor-
tion of 4-sulfated disaccharide for children as compared to
adults, the chemical and enzymatic analyses have shown simi-
lar sulfation levels for normal and stone-forming urinary chon-
droitin and heparan sulfates from both adults and children.
Other investigators found differences between normal and stone
forming urines, in terms of degree of sulfation of the GAG [8],
although such a difference has not been found iii the present
investigation for either chondroitin sulfate or heparan sulfate.
The urinary heparan sulfates have shown higher molecular
weights as compared to the chondroitin sulfates (35,000 and
5,000, respectively).
The results here presented indicate that there is a definite
difference with respect to the levels of GAG between normal
and stone forming urines, although there is no structural differ-
ence in urinary GAG from these subjects. This result raises the
possibility that urinary GAG concentrations play an important
role in the production and retention of calculi. However, it is
unlikely that they alone can be held responsible for the total
control of urolithiasis. Rather, their action in association with
both small and macro-urinary components should be synergic in
preventing urolithiasis.
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